Skip to search formSkip to main contentSkip to account menu

crenolanib

Known as: [1-[2-[5-(3-Methyloxetan-3-ylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-yl]amine, PDGFR Inhibitor CP-868596, PDGFR inhibitor CP-868,596 
An orally bioavailable benzimidazole targeting the platelet-derived growth factor receptor (PDGFR) subtypes alpha and beta and FMS-related tyrosine… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (3)

Antineoplastic AgentsBenzimidazolesPiperidines

Narrower (1)

CP-868,596
Inhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPlatelet-Derived Growth Factor ReceptorPositive Regulation of Apoptosis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Crenolanib versus midostaurin combined with induction and consolidation chemotherapy in newly diagnosed FLT3 mutated AML.
TPS7068 Background: Despite the approval of multi-targeted protein kinase inhibitor midostaurin for use in combination with… 
2018
2018
Addition of Crenolanib to Induction Chemotherapy Overcomes the Poor Prognostic Impact of Co- Occurring Driver Mutations in Patients with Newly Diagnosed FLT3-Mutated AML
Background: Patients with AML harboring FLT3 mutations have poor clinical outcomes. Furthermore, FLT3 mutations frequently co… 
2018
2018
Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant
Background: FLT3 inhibitors (like sorafenib and midostaurin) have been administered as maintenance therapy post allogeneic stem… 
2017
2017
A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study.
TPS11080Background: Activating mutations in the kinase domain of PDGFRA account for 10-15% of GIST. The most common PDGFRA… 
2016
2016
Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML
Background: High-dose cytarabine and mitoxantrone (HAM) have been used as salvage chemotherapy in patients (pts) with relapsed… 
2016
2016
Efficacy of a Type I FLT3 Inhibitor, Crenolanib, with Idarubicin and High-Dose Ara-C in Multiply Relapsed/Refractory FLT3+ AML
Background: Crenolanib is a novel, type I, oral pan-FLT3 inhibitor with in vitro activity against FLT3-ITD and FLT3-tyrosine… 
2015
2015
Full Doses of Crenolanib, a Type I FLT3 Inhibitor, Can be Safely Administered in AML Patients Post Allogeneic Stem Cell Transplant
Abstract Introduction: Crenolanib besylate is a selective and potent type I tyrosine kinase inhibitor (TKI) of wild-type and… 
2015
2015
Population Pharmacokinetics of Crenolanib, a Type I FLT3 Inhibitor, in Patients with Relapsed/Refractory AML
Background: Crenolanib besylate is a selective and potent type I tyrosine kinase inhibitor (TKI) of wild-type and mutant FMS-like… 
2013
2013
Large-scale Analysis of PDGFRA Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib
Purpose: Platelet-derived growth factor receptor α (PDGFRA) is a target for tyrosine kinase inhibitor (TKI)-based targeted… 
2012
2012
Abstract 3660: Crenolanib: A next generation FLT3 inhibitor
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Every year in the US there are approximately 12… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)